Keith Roizman, Founder, Executive Chairman and Chief Technology Officer

Mr. Roizman is patient advocate, and entrepreneur in the field of retinal science and medicine since he was diagnosed with a retinal degenerative eye disorder in 1991. Roizman was Founder, President and Chief Executive Officer of Photogenesis, Inc., the first company in the world to perform a 10-patient clinical study using intact retinal cell layers of both retinal pigment epithelial and photoreceptor cells from adult human donor eyes for the treatment of age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Under Mr. Roizman’s leadership, Photogenesis acquired and/or developed the intellectual property and platform technology that is the foundation for the way all forms of stem-cell-derived retinal cell layers are being used in current treatments for retinal eye diseases. Mr. Roizman is the inventor and/or co-inventor for Macregen’s intellectual property, including the Company’s platform technology, Ophthamize™, using cell-penetrating peptides in combination with numerous drugs to potentially treat a broad spectrum of eye diseases. Roizman identified the opportunity for MacRegen’s lead drug candidate, Mitia™, which has significant potential as a disease-modifying drug for the treatment of all forms of AMD.
Since Mr. Roizman became involved in the field of retinal science and medicine, he has been responsible for raising many millions of dollars as an entrepreneur as well as for several prominent academic research institutions. Prior to Mr. Roizman being diagnosed with RP, he had a successful career as an architectural designer, master planner and inovator for a number of the largest high-technology civic structures around the world which were valued in the many billions of dollars. Included among these works were the master plans and buildings for Market Street East in Philadelphia, Melbourne Park and Rod Laver Arena in Melbourne, the new Parliament House and Capitol in Canberra, and Darling Harbor Master Plan and Exhibition Center in Sydney, Australia. Mr. Roizman is a proud alumnus of Temple University where he attended both the Schools of Architecture and Engineering in Philadelphia, as well as the Tyler School of Art in Rome, Italy. Roizman is an auto-didact, futurist and an anticipatory design scientist and inventor in numerous disciplines.

B. Michael Silber, Ph.D., Founder, President and Chief Executive Officer

In addition to his responsibilities at MacRegen, Inc., Dr. Silber is also Professor, Department of Bioengineering and Therapeutic Sciences, University of California San Francisco (UCSF), Schools of Medicine and Pharmacy, and a Senior Advisor at several companies and Scientific Advisory Board member at Optivia. Until recently, he was also Professor of Neurology and Chief of Drug Discovery at UCSF.  Additional background includes that as President and CEO of Reiley Pharmaceuticals, Inc., President and CEO of Elmedtech, Inc., Senior Vice President of research and development (R & D) at Roche, Vice President of R & D and Chief Scientific Officer at ALZA/Johnson & Johnson, Director of R & D at Pfizer, Senior Director of R & D at Cetus, and Director of R & D at Lederle Labs, on the Scientific Advisory Board of five companies and Board member at two Universities.
Dr. Silber has contributed to the discovery, preclinical and/or clinical development, registration, or commercial success of 23 biotechnology and small molecule drugs approved around the world in many disease areas.  These include 13 “blockbuster” drugs like Lipitor®, Remicade®, Aricept®, Celebrex®, Betaseron®, Duragesic®, Concerta®, Procrit®, Geodon®, Norvasc®, Zithromax®, Zoloft®, and Suprax®.  His leadership contributed to the nomination of over 250 potential medicines that advanced into clinical development across many of the most important diseases with high unmet medical need.  He is the author of more than 215 peer-reviewed publications (http://profiles.ucsf.edu/michael.silber) and book chapters, patents, abstracts, and invited presentations.  Dr. Silber has a deep knowledge of disease pathogenesis in many areas of medicine, therapeutics across many important diseases, and all key scientific areas of drug discovery, pre-clinical and clinical development, regulatory approval and commercialization. Dr. Silber has led diligence and investment decisions in large and small companies and has successfully raised capital in private and academic institutions. He is or has been a contributor, advisor, or board member in private, start-up, public, and academic organizations.  Dr. Silber received a Ph.D. from UCSF and a Doctorate from the University of Southern California.

Christine A. Curcio Ph.D., Chief Scientific Officer

Christine A. Curcio, PhD, is Professor of Ophthalmology and Visual Sciences at the University of Alabama at Birmingham, and an internationally recognized leader on age-related macular degeneration (AMD) pathobiology and validation of clinical imaging technology. Dr. Curcio has 34 years’ experience in multi-disciplinary studies of human donor eyes through by a productive collaboration with the Alabama Eye Bank, an industry leader in rapid tissue recovery. Dr. Curcio has published more than 165 peer review papers and delivered more than 240 invited presentations on 4 continents. Over 29 years, as Principle Investigator or co-Investigator on NIH-funded and foundation grants, she established that the human macula is dominated by rod photoreceptors and that rod loss in the central macula is a major feature of human retinal aging. These highly cited studies quantitatively validated and provided visualization targets for single-cell imaging of photoreceptors and helped motivate the development of dark adaptometry as an outcome measure for early AMD trials.

From  1998-2011 Dr. Curcio focused on the ultrastructure, composition, and biologic context of ‘membranous debris’ the largest component of soft drusen, AMD’s specific deposit, establishing that the retinal pigment epithelium is a constitutive lipoprotein secretor. The diet-driven ‘Oil Spill’ hypothesis received important experimental confirmation in 2017 and is the basis of Macregen’s breakthrough AMD drug candidate Mitia™ to scavenge and remove retinal lipids. Since 2009, Dr. Curcio focused on the subcellular basis of optical coherence tomography (OCT) and fundus autofluorescence, two essential diagnostic imaging tools for outer retinal disease especially AMD. Using donor eyes accessioned over 15 years Dr. Curcio created Project MACULA (project MACULA website), an online digital microscope to explore high-resolution histology of AMD and normal eyes. This resource allowed Dr. Curcio and her expert clinical collaborators to provide the first and most comprehensive histologic descriptions and corresponding OCT signatures for key aspects of AMD pathology, including subretinal drusenoid deposit, outer retinal tubulation, migratory retinal pigment epithelium, persistent basal laminar deposit, refractile drusen, lipid globules, and clinicopathologic correlation for types 1 and 3 neovascularization. Dr. Curcio's currently-funded research focuses on the molecular and subcellular basis of hyperspectral autofluorescence imaging including retinal lipid discovery through imaging mass spectrometry. Dr. Curcio was educated at Brown University (ScB), University of Rochester (PhD), Boston University (post-doctoral), and the University of Washington (research faculty).

Robert Scott MD., Principal Consultant for Topical Drug Delivery

Professor Robert Scott is a consultant ophthalmologist with subspecialist clinical interests in retinal disease and ocular trauma. Dr. Scott qualified from St Thomas’ Hospital in London in 1987 and specialized in ophthalmology at Queens Medical Centre, Nottingham and Moorfields Eye Hospital, London. Dr. Scott attained dual Fellowship of the Royal College of Ophthalmologists and Royal College of Surgeons of Edinburgh in 1993.  Dr. Scott served for 26 years in the Royal Air Force and as the lead military consultant ophthalmologist at the Royal Center for Defence Medicine, Birmingham for 15 years where he treated the soldiers with eye injuries brought back to the UK from the wars in Iraq and Afghanistan. During this time, Dr. Scott has served as the Royal Air Force and Defence Medical Services Consultant Adviser in Ophthalmology. Dr. Scott’s work with artificial vision for the war-blinded was featured on the acclaimed BBC documentary ‘Frontline Medicine’.

Dr. Scott’s Doctorate in Medicine was from the University of Nottingham and he is widely published in the scientific press co-authoring around 100 peer-reviewed scientific papers. Dr. Scott is a co-inventor of the Cell Penetrating Peptide and has worked to develop its use as a platform to deliver new generation medicines to the eye.  Dr. Scott was honored to be elected as President of the Midland Ophthalmological Society in 2008, appointed as the Defence Medical Services and Royal College of Ophthalmologists Professor of Ophthalmology in 2012, then honorary Professor of Ophthalmology by the University of Birmingham in 2014.  Dr. Scott  was named as a Times newspaper top UK surgeon for all specialties in 2011 and awarded the Lady Cade Medal for research by the Royal College of Surgeons of England in 2014.  On retiring from the RAF, Dr. Scott served as medical director for Moorfields Eye Hospital in Dubai, where he helped build a new eye hospital in Abu Dhabi. Returning to the UK in 2017, Dr. Scott helped the expansion of the NHS cataract provider SpaMedica Ltd, from 6 to 10 hospitals. Dr. Scott has recently formed his own healthcare provider company, ScottHealth Ltd, to deliver ophthalmic surgical and consultancy services to NHS and private hospitals. 

Robyn Guymer, MBBS, PhD, Principal Consultant for Clinical Affairs

Robyn Guymer is Professor of Ophthalmology at the University of Melbourne and a Deputy Director of the Centre for Eye Research Australia (CERA). Dr. Guymer is also a senior retinal specialist at the Royal Victorian Eye and Ear Hospital. She is a clinician scientist who leads a team of 20 researchers primarily investigating age-related macular degeneration (AMD).  Dr. Guymer is currently investigating new strategies for treating early stages of AMD with a nanosecond laser and is working to identify novel imaging and functional biomarkers and surrogate endpoints to improve the feasibility of conducting early intervention trials. She has been a principal investigator in many industry sponsored trials and serves on several pharmaceutical advisory boards. Dr. Guymer is part of the International Mactel consortium, the Beckman/Ryan AMD initiative (USA) and the International Classification of Atrophy (CAM) group. She is a member of the Macular Society and an inaugural fellow of the Australian Academy of Health and Medical Sciences.  Dr. Guymer was awarded the NHMRC’s 2016 Elizabeth Blackburn Fellowship for the top ranked female research fellowship in clinical medicine. In June 2018, she was awarded the Member of the Order of Australia (AM) for significant service to medicine in the field of ophthalmology, particularly AMD as a clinician, academic and researcher.

Matthew Hemington JD., General Counsel and Secretary of the Board of Directors

Matthew Hemington is a partner at Cooley LLP and has been practicing  with Cooley for more than 25 years in Silicon Valley. He has substantial experience in representing emerging growth companies, venture capitalists, corporate investors and public companies, such as Morgan Stanley Ventures, Intersect ENT, Cymabay Therapeutics, Scynexis, Inc. and SI-Bone. Matt has advised emerging technology companies in matters ranging from startup incorporation and counseling to day-to-day representation of public companies. His practice also focuses on the representation of healthcare, medtech and digital health companies.  Matt has assisted his clients with obtaining financing, technology and licensing matters, public offerings, merger and acquisitions, strategic relationships and executive compensation matters. Since 2010, Mr. Hemington has been recognized in the Best Lawyers in America for Venture Capital Law, Securities/Capital Markets Law and Corporate Law. Prior to attending law school at University of California - Los Angeles, Matt was a staff accountant in the San Francisco tax department of Arthur Anderson & Co. and he graduated from the University of California - Berkeley with a Bachelor of Economics with Honors.

Macregen Inc. website designed by Igor Knezevic